DefiniGEN is one of the first commercial opportunities to arise from Cambridge’s expertise in stem cell research. Here, we look at some of the fundamental research that enables it to supply liver and pancreatic cells for drug screening.
Cambridge team which developed method to generate liver cells from skin cells has formed a new company to supply stem cell products to the drug discovery and regenerative medicine sectors.
<p>Research paves way for new liver disease research and possibly cell-based therapy.<br /> &nbsp;
© 2024 University of Cambridge